Relapse Prevention With Varenicline (0815)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00944554|
Recruitment Status : Completed
First Posted : July 23, 2009
Results First Posted : June 23, 2017
Last Update Posted : August 3, 2017
|Condition or disease||Intervention/treatment||Phase|
|Recurrence Smoking Cessation Substance-Related Disorders||Drug: Varenicline Drug: Placebo||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||104 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Relapse Prevention With Varenicline|
|Study Start Date :||October 2008|
|Actual Primary Completion Date :||May 2011|
|Actual Study Completion Date :||May 2011|
Placebo Comparator: Placebo
Group given placebo.
Placebo given twice a day or five weeks.
Experimental group given varenicline dosing.
Varenicline given twice a day or five weeks.
Other Name: Varenicline (Chantix®)
- Days to Relapse [ Time Frame: 4 weeks ]Number of days following the programmed lapse exposure until relapse to smoking occurred
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00944554
|United States, Maryland|
|Behavioral Pharmacology Research Unit|
|Baltimore, Maryland, United States, 21224|
|Principal Investigator:||Maxine L Stitzer, PhD||Johns Hopkins University|